• We provide here direct evidences that AT receptors are activ

  2024-05-24

  

  We provide here direct evidences that AT1 receptors are active in ADSCs since Ang II induces intracellular Ca mobilization in these cells. Data obtained during the observation of Ca influxes led us to the search for the ADSCs subpopulation constantly expressing AT1 receptor. ADSCs are necessary for

• Whether similar mechanisms play a

  2024-05-23

  

  Whether similar mechanisms play a role in adiponectin signal transduction and whether additional proteins are recruited to adiponectin receptors via APPL1 has not been analysed so far. Although it has been clearly established that APPL1 is a downstream adaptor protein in adiponectin signal transduct

• AdipoRon is an orally active synthetic small molecule that a

  2024-05-23

  

  AdipoRon is an orally active, synthetic small molecule that activates adiponectin receptor (AdipoR). It mimics the antidiabetic effects of adiponectin, exhibiting its effect through the activation of AMPK and PPARα pathways via AdipoR1 and AdipoR2, respectively (Fig. 2) [62]. AdipoR activation has r

• br Acknowledgements This work was supported by Conselho

  2024-05-23

  

  Acknowledgements This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) FINEP research grant “Rede Instituto Brasil

• angiotensin ii receptor blockers br Introduction Myasthenia

  2024-05-23

  

  Introduction Myasthenia gravis (MG) is an autoimmune disease in which antibodies against targets on the postsynaptic muscle membrane cause neuromuscular transmission failure. About 85% of patients with MG have autoantibodies against angiotensin ii receptor blockers receptor (AChR) [1]. In AChR n

• br Results and discussion br

  2024-05-23

  

  Results and discussion Conclusions In this report we present the synthesis, structure determination, and the in vitro and in vivo evaluation of a series of new quinone analogues aiming to find novel lead structures for the development of 5-LO inhibitors. Our findings support that also the hydr

• Further analysis sought to understand the

  2024-05-23

  

  Further analysis sought to understand the mechanism associated with the autotaxin-mediated increase of miR-489-3p in circulation. Based upon sequence complementarity, DIANA TarBase predicted miR-489-3p targets MAPK2K1, or MEK1, an oncogene widely dysregulated in cancer (Fig. 4A). To test this relati

• Purification of Rv c In order

  2024-05-23

  

  Purification of Rv2477c. In order to investigate the catalytic capabilities of Rv2477c, we expressed the protein as an N-terminal histidine-tagged fusion protein in E. coli BL21 cells and purified the protein by cobalt-affinity chromatography. As shown in Fig. 2A, the 65 kDa fusion protein was expre

• br Conclusion br Acknowledgements br Introduction Synapses

  2024-05-23

  

  Conclusion Acknowledgements Introduction Synapses are the fundamental elements of neuronal networks that enable the processing, encoding, and retrieval of information in the brain, and pathological disruptions in synapse structure are broadly held to underlie the development of neurological

• The approach of enzymatically converting an analyte

  2024-05-22

  

  The approach of enzymatically converting an analyte and detecting it by the resulting small pH changes near the reduced graphene oxide (rGO) surface has successfully been pursued in case of urea (Piccinini et al., 2017). Furthermore, this work reported that electrostatic layer-by-layer (LbL) assembl

• In spite of this unexpectedly after three

  2024-05-22

  

  In spite of this, unexpectedly, after three-week cherry puree consumption no AC increase was observed, irrespective of the method used (Table 2). A statistically significant decrease of AC was even measured by LOX-FL and ORAC methods (−3.5% and −9%, respectively). Nevertheless, a much more evident d

• No starting dose adjustment is needed

  2024-05-22

  

  No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad

• Introduction Alzheimer s disease AD is

  2024-05-22

  

  Introduction Alzheimer's disease (AD) is a complex neurological disorder characterized by a progressive dementia resulting from synapse failure (Selkoe, 2002, Tanzi, 2005). The amyloid hypothesis maintains that the pivotal event in AD is the production of amyloid-β (Aβ) peptides following the prote

• br Discussion Hepatic dysfunction in the metabolic syndrome

  2024-05-22

  

  Discussion Hepatic dysfunction in the metabolic syndrome is a driver of negative patient outcomes that requires more therapeutic options. The complexity of liver alterations in this disease – elevated de novo synthesis of fatty acids and cholesterol, reduced clearance of circulating atherogenic L

• Imaging QTL studies may have

  2024-05-22

  

  Imaging QTL studies may have several potential advantages over case-control studies, including increased power . Imaging endophenotypes of disease in QTL studies can separate patients and normal subjects more accurately and therefore limit the confound of including asymptomatic subjects in the contr

15922 records 147/1062 page Previous Next First page 上5页 146147148149150 下5页 Last page